VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results indicate potential for reducing off-target toxicity common with traditional ADCs. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
The company maintains a diversified oncology pipeline of antibody-based formats including ADCs, T-cell engagers (TCEs), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
These developments underscore VERAXA's commitment to advancing next-generation cancer therapies that offer improved efficacy and safety profiles. The ability to selectively target cancer cells while sparing healthy tissue addresses a critical need in oncology, where treatment-related toxicities often limit dosing and patient outcomes. As VERAXA progresses its BiTAC platforms toward clinical development, the company aims to establish partnerships that can accelerate the translation of these technologies into viable treatment options.
Investors and industry observers are closely watching VERAXA’s progress, given the growing interest in precision oncology and the potential of BiTAC technology to differentiate from existing ADC and TCE modalities. The company’s recent listing on NASDAQ provides access to capital markets to support its research and development efforts. Further updates on VERAXA’s pipeline and partnership activities are expected as the company engages with potential collaborators at the BIO convention and beyond.
For more information, visit the company’s newsroom at https://nnw.fm/VRXA.
